NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Sees Large Decline in Short Interest

by · The Cerbat Gem

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Get Free Report) was the target of a large drop in short interest in the month of September. As of September 15th, there was short interest totalling 385,600 shares, a drop of 18.1% from the August 31st total of 470,700 shares. Currently, 2.7% of the shares of the stock are sold short. Based on an average daily volume of 392,400 shares, the days-to-cover ratio is presently 1.0 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in NeuroSense Therapeutics stock. XTX Topco Ltd acquired a new position in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 32,650 shares of the company’s stock, valued at approximately $37,000. XTX Topco Ltd owned approximately 0.24% of NeuroSense Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.04% of the company’s stock.

NeuroSense Therapeutics Trading Up 0.8 %

Shares of NRSN stock traded up $0.01 during trading hours on Monday, reaching $1.28. The stock had a trading volume of 64,400 shares, compared to its average volume of 278,903. The stock’s fifty day simple moving average is $0.93 and its 200 day simple moving average is $1.15. The firm has a market capitalization of $17.49 million, a PE ratio of -1.51 and a beta of 1.52. NeuroSense Therapeutics has a 12 month low of $0.40 and a 12 month high of $2.33.

About NeuroSense Therapeutics

(Get Free Report)

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company’s lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer’s, as well as under preclinical studies for the treatment of Parkinson’s disease.

Further Reading